ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

被引：1
|
作者：
Bailleux, Caroline
Bachelot, Thomas
Bidard, Francois-Clement
Hardy-Bessard, Anne-Claire
Bieche, Ivan
Pradines, Anne
Clatot, Florian
Rouge, Thibault De La Motte
Canon, Jean-Luc
Pistilli, Barbara
Chang, Kyle
Quinn, Katie J.
Gustafson, Heather L.
Dalenc, Florence
Foa, Cyril
Ammarguellat, Hanifa
Bernard-Marty, Chantal
Lucas, Brigitte
Barthier, Sophie
Lorchel, Fabrice
Gisserot, Olivier
Arnould, Laurent
Mauduit, Marjorie
Lemonnier, Jerome
Berger, Frederique
Delaloge, Suzette
Andre, Fabrice
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
  • [32] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Hart, Christopher D.
    Migliaccio, Ilenia
    Malorni, Luca
    Guarducci, Cristina
    Biganzoli, Laura
    Di Leo, Angelo
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
  • [33] Protein-protein interaction of HER2 predicts the prognosis of hormone receptor-positive HER2-negative breast cancer
    Choi, Hee Jun
    Lee, Hong Won
    Kim, Sangmin
    Yoon, Tae-Young
    Kim, Hyunwoo
    Lee, Seul
    Nam, Seok Jin
    Kim, Seok Won
    Cho, Sooyoun
    Park, Yeon Hee
    Lee, Jeong Eon
    CANCER RESEARCH, 2020, 80 (04)
  • [34] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [35] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [36] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [37] Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database
    Pflumio, C.
    Carton, M.
    Debled, M.
    Cottu, P. H.
    Leheurteur, M.
    Dalenc, F.
    Jacot, W.
    Mailliez, A.
    Sauterey, B.
    Levy, C.
    Kaderbhai, C.
    Tredan, O.
    Goncalves, A.
    Uwer, L.
    Robert, M.
    Bailleux, C.
    Cabel, L.
    Delaloge, S.
    Bosquet, L.
    Petit, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S374 - S375
  • [38] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [40] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
12345